280 related articles for article (PubMed ID: 16419069)
41. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy.
Bruins HM; Huang GJ; Cai J; Skinner DG; Stein JP; Penson DF
J Urol; 2009 Nov; 182(5):2182-7. PubMed ID: 19758623
[TBL] [Abstract][Full Text] [Related]
43. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer.
Smith MR; Kantoff PW
Semin Oncol; 1995 Dec; 22(6):625-32. PubMed ID: 8539637
[TBL] [Abstract][Full Text] [Related]
45. Defining optimal therapy for muscle invasive bladder cancer.
Herr HW; Dotan Z; Donat SM; Bajorin DF
J Urol; 2007 Feb; 177(2):437-43. PubMed ID: 17222605
[TBL] [Abstract][Full Text] [Related]
46. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
Chung PW; Bristow RG; Milosevic MF; Yi QL; Jewett MA; Warde PR; Catton CN; McLean M; Moore M; Tannock IF; Gospodarowicz MK
Urol Oncol; 2007; 25(4):303-9. PubMed ID: 17628296
[TBL] [Abstract][Full Text] [Related]
47. Bladder-sparing therapy for muscle-infiltrating bladder cancer.
Pansadoro V; Emiliozzi P
Nat Clin Pract Urol; 2008 Jul; 5(7):368-75. PubMed ID: 18560383
[TBL] [Abstract][Full Text] [Related]
48. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
[TBL] [Abstract][Full Text] [Related]
49. [Neoadjuvant chemotherapy in muscle-invasive bladder cancer].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1745-9. PubMed ID: 18030008
[TBL] [Abstract][Full Text] [Related]
50. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant chemotherapy in lymph node positive bladder cancer.
Gofrit ON; Stadler WM; Zorn KC; Lin S; Silvestre J; Shalhav AL; Zagaja GP; Steinberg GD
Urol Oncol; 2009; 27(2):160-4. PubMed ID: 18440835
[TBL] [Abstract][Full Text] [Related]
52. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review.
Pectasides D; Pectasides M; Nikolaou M
Eur Urol; 2005 Jul; 48(1):60-7; discussion 67-8. PubMed ID: 15967253
[TBL] [Abstract][Full Text] [Related]
54. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.
Amiel GE; Lerner SP
Expert Rev Anticancer Ther; 2006 Feb; 6(2):281-91. PubMed ID: 16445380
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.
Walz J; Shariat SF; Suardi N; Perrotte P; Lotan Y; Palapattu GS; Gupta A; Bastian PJ; Rogers CG; Vazina A; Amiel GE; Sagalowsky AI; Schoenberg M; Lerner SP; Karakiewicz PI
BJU Int; 2008 Jun; 101(11):1356-61. PubMed ID: 18454792
[TBL] [Abstract][Full Text] [Related]
56. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.
Bria E; Giannarelli D; Felici A; Peters WP; Nisticò C; Vanni B; Cuppone F; Cognetti F; Terzoli E
Cancer; 2005 Feb; 103(4):672-9. PubMed ID: 15637696
[TBL] [Abstract][Full Text] [Related]
57. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Tsai YS; Tzai TS; Chow NH
Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
[TBL] [Abstract][Full Text] [Related]
58. Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer.
Bruins HM; Stein JP
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1091-101. PubMed ID: 18588454
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer.
Sternberg CN; Parmar MK
J Clin Oncol; 2001 Sep; 19(18 Suppl):21S-26S. PubMed ID: 11560967
[No Abstract] [Full Text] [Related]
60. Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: current standards.
Dreicer R
Urol Oncol; 2007; 25(1):72-5. PubMed ID: 17208143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
